RxDoctor Payments Data

Shannon Smiley, MD

Hematology & Oncology · Anchorage, AKNPI 1891715942

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,950 of the $6,186 with a category attached, or 80.0%. 23 manufacturers reported payments, led by CSL Behring at 44.9% of the total. Reporting peaked in 2022 at $3,923 and has fallen 83.4% since, to $651 in 2025.

$6,186in general payments, 2019–2025

Across 54 payments — averaging $114.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$3K
  • National Marrow Donor Program$2K
  • Johnson & Johnson$199
  • Novartis$155
  • GSK$115
  • Genentech USA, Inc.$105
  • plus $662 from 17 others

What the payments were for

  • Consulting fees$4,95080%
  • Food & beverage$1,03717%
  • Education$1993%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few hematology & oncology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$4,159,961
Medicare patients
551
Services billed
159,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate32$481,005
TagrissoOsimertinib Mesylate17$415,433
Lenalidomide20$306,556
ImbruvicaIbrutinib16$286,790
JakafiRuxolitinib Phosphate16$272,931
LumakrasSotorasib13$268,698
PomalystPomalidomide11$253,997
RevlimidLenalidomide11$215,008
EliquisApixaban18$16,721
XareltoRivaroxaban16$13,183
Acyclovir62$1,587
Anastrozole36$1,222
Levothyroxine Sodium12$1,206
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen39$698
Gabapentin27$649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence, Tagrisso$25$896,43849 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$24$286,79016 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$27$253,99711 claims
PfizerEliquis$93$16,72118 claims
Johnson & JohnsonXarelto$199$13,18316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology & oncology providers in Alaskaon file to place this against a meaningful peer group, so we don't.

Other hematology & oncology in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →